AstraZeneca Pharma India Limited will launch Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in November 2025 in India.

Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients.

The company received the receipt of Import and Marketing Permission in Form CT-20 from the Drugs Controller General of India in March 2025 for Sodium Zirconium Cyclosilicate powder for oral suspension 5 g and 10 g (Lokelma).